Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice

Annals of Neurology

Volumn 80, Issue 5, 2016, Pages 766-775

  Migdalska Richards, Anna ^a   Daly, Liam ^a   Bezard, Erwan ^b,c   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMBROXOL; GLUCOSYLCERAMIDASE; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG; EXPECTORANT AGENT; SNCA PROTEIN, HUMAN; SNCA PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN STEM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GENE MUTATION; HETEROZYGOTE; MESENCEPHALON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GAUCHER DISEASE; HUMAN; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; AMBROXOL; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EXPECTORANTS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MICE; MICE, TRANSGENIC; PARKINSON DISEASE;

EID: 84995802014     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24790     Document Type: Article

References (35)

1. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 2010;33:167–173.
2. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651–1661.
3. McNeill A, Duran R, Hughes DA, et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012;83:853–854.
4. McNeill A, Duran R, Proukakis C, et al. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 2012;27:526–532.
5. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010;6:309–317.
6. Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev Neurosci 2013;24:115–123.
7. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012;11:986–998.
8. Cullen V, Sardi SP, Ng J, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 2011;69:940–953.
9. Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A 2013;110:3537–3542.
10. Xu YH, Xu K, Sun Y, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet 2014;23:3943–3957.
11. Manning-Bog AB, Schule B, Langston JW. Alpha synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009;30:1127–1132.
12. Cleeter MW, Chau KY, Gluck C, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013;62:1–7.
13. Osellame LD, Rahim AA, Hargreaves IP, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease. Cell Metab 2013;17:941–953.
14. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37–52.
15. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012;72:455–463.
16. Murphy KE, Halliday GM. Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy 2014;10:1350–1351.
17. Sawkar AR, Cheng WC, Beutler E, et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 2002;99:15428–15433.
18. Steet RA, Chung S, Wustman B, et al. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A 2006;103:13813–13818.
19. Maegawa GH, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009;284:23502–23516.
20. Bendikov-Bar I, Ron I, Filocamo M, Horowitz M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis 2011;46:4–10.
21. Bendikov-Bar I, Maor G, Filocamo M, Horowitz M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis 2013;50:141–145.
22. Patnaik S, Zheng W, Choi JH, et al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem 2012;55:5734–5748.
23. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137:1481–1495.
24. Luan Z, Li L, Higaki K, et al. The chaperone activity and toxicity of ambroxol on Gaucher cells and wild-type mice. Brain Dev 2013;35:317–322.
25. Sanders A, Hemmelgarn H, Melrose H, et al. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease. Blood Cells Mol Dis 2013;51:109–115.
26. Liu Y, Suzuki K, Reed JD, et al. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci U S A 1998;95:2503–2508.
27. Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin Genet 1978;13:145–153.
28. Wendeler M, Sandhoff K. Hexosaminidase assays. Glycoconj J 2009;26:945–952.
29. Vaccaro AM, Ciaffoni F, Tatti M, et al. pH-dependent conformational properties of saposins and their interaction with phospholipid membranes. J Biol Chem 1995;270:30576–30580.
30. Sun Y, Qi X and Grabowski GA. Saposin C is required for wild-type resistance of acid b-glucosidase to proteolytic degradation. J Biol Chem 2003;278:31918–31923.
31. Gispert S, Del Turco D, Garrett L, et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 2003;24:419–429.
32. Oueslati A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis 2016;6:39–51.
33. Schapira AH, Gegg ME. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A 2013;110:3214–3215.
34. Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015;66(pt A):37–42.
35. Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem 2016;139:77–90.